

- A retrospective cohort study. *Aliment Pharmacol Ther.* 2015;41:747–57.
109. Salerno F, Navickis RJ, Wilkes MM. Albumin treatment regimen for type 1 hepatorenal syndrome: A dose-response meta-analysis. *BMC Gastroenterol.* 2015;15:167.
 110. Arora V, Vijayaraghavan R, Maiwall R, Sahney A, Thomas SS, Ali R, et al. Paracentesis-Induced Circulatory Dysfunction With Modest-Volume Paracentesis Is Partly Ameliorated by Albumin Infusion in Acute-on-Chronic Liver Failure. *Hepatology.* 2020;72:1043–55.
 111. Wong F, Angeli P. New diagnostic criteria and management of acute kidney injury. *J Hepatol.* 2017;66:860–1.
 112. Wong F, Pappas SC, Curry MP, Reddy KR, Rubin RA, Porayko MK, et al. Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome. *N Engl J Med.* 2021;384:818–28.
 113. Facciorusso A, Chandar AK, Murad MH, Prokop LJ, Muscatiello N, Kamath PS, et al. Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: A systematic review and network meta-analysis. *Lancet Gastroenterol Hepatol.* 2017;2:94–102.
 114. Martin-Llahi M, Pepin MN, Guevara M, Diaz F, Torre A, Monescillo A, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: A randomized study. *Gastroenterology.* 2008;134:1352–9.
 115. Sanyal AJ, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. *Gastroenterology.* 2008;134:1360–8.
 116. Boyer TD, Sanyal AJ, Wong F, Frederick RT, Lake JR, O'Leary JG, et al. Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1. *Gastroenterology.* 2016;150:1579–589 e1572.
 117. Nazar A, Pereira GH, Guevara M, Martin-Llahi M, Pepin MN, Marinelli M, et al. Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. *Hepatology.* 2010;51:219–26.
 118. Boyer TD, Sanyal AJ, Garcia-Tsao G, Blei A, Carl D, Bexon AS, et al. Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: Relationship of serum creatinine to hemodynamics. *J Hepatol.* 2011;55:315–21.
 119. Sanyal AJ, Boyer TD, Frederick RT, Wong F, Rossaro L, Araya V, et al. Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies. *Aliment Pharmacol Ther.* 2017;45:1390–402.
 120. Piano S, Schmidt HH, Ariza X, Amoros A, Romano A, Husing-Kabar A, et al. Association Between Grade of Acute on Chronic Liver Failure and Response to Terlipressin and Albumin in Patients With Hepatorenal Syndrome. *Clin Gastroenterol Hepatol.* 2018;16:1792–1800 e1793.
 121. Cavallin M, Kamath PS, Merli M, Fasolato S, Toniutto P, Salerno F, et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial. *Hepatology.* 2015;62:567–74.
 122. Wong F, Boyer TD, Sanyal AJ, Pappas SC, Escalante S, Jamil K. Reduction in acute kidney injury stage predicts survival in patients with type-1 hepatorenal syndrome. *Nephrol Dial Transplant.* 2020;35:1554–61.
 123. Belcher JM, Coca SG, Parikh CR. Creatinine Change on Vasoconstrictors as Mortality Surrogate in Hepatorenal Syndrome: Systematic Review & Meta-Analysis. *PLoS One.* 2015;10:e0135625.
 124. Arora V, Maiwall R, Rajan V, Jindal A, Muralikrishna Shasthry S, Kumar G, et al. Terlipressin Is Superior to Noradrenaline in the Management of Acute Kidney Injury in Acute on Chronic Liver Failure. *Hepatology.* 2020;71:600–10.
 125. Alessandria C, Ottobrelli A, Debernardi-Venon W, Todros L, Cerenzia MT, Martini S, et al. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: A prospective, randomized, unblinded, pilot study. *J Hepatol.* 2007;47:499–505.
 126. Sharma P, Kumar A, Shrama BC, Sarin SK. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. *Am J Gastroenterol.* 2008;103:1689–97.
 127. Singh V, Ghosh S, Singh B, Kumar P, Sharma N, Bhalla A, et al. Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: A randomized study. *J Hepatol.* 2012;56:1293–8.
 128. Goyal O, Sidhu SS, Sehgal N, Puri S. Noradrenaline is as Effective as Terlipressin in Hepatorenal Syndrome Type 1: A Prospective, Randomized Trial. *J Assoc Physicians India.* 2016;64:30–5.
 129. Saif RU, Dar HA, Sofi SM, Andrabi MS, Javid G, Zargar SA. Noradrenaline versus terlipressin in the management of type 1 hepatorenal syndrome: A randomized controlled study. *Indian J Gastroenterol.* 2018;37:424–9.
 130. Nassar Junior AP, Farias AQ, LA DA, Carrilho FJ, Malbouisson LM. Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome: A systematic review and meta-analysis. *PLoS One.* 2014;9:e107466.
 131. Gifford FJ, Morling JR, Fallowfield JA. Systematic review with meta-analysis: Vasoactive drugs for the treatment of hepatorenal syndrome type 1. *Aliment Pharmacol Ther.* 2017;45:593–603.
 132. Best LM, Freeman SC, Sutton AJ, Cooper NJ, Tng EL, Csenar M, et al. Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: A network meta-analysis. *Cochrane Database Syst Rev.* 2019;9:CD013103.
 133. Kwong A, Kim WR, Kwo PY, Wang U, Cheng X. Feasibility and Effectiveness of Norepinephrine Outside the Intensive Care Setting for Treatment of Hepatorenal Syndrome. *Liver Transpl.* 2021;27:1095–105.
 134. Allegretti AS, Parada XV, Eneanya ND, Gilligan H, Xu D, Zhao S, et al. Prognosis of Patients with Cirrhosis and AKI Who Initiate RRT. *Clin J Am Soc Nephrol.* 2018;13:16–25.
 135. Gonwa TA, Wadei HM. The challenges of providing renal replacement therapy in decompensated liver cirrhosis. *Blood Purif.* 2012;33:144–8.
 136. Investigators S-A, Canadian Critical Care Trials G, Australian, New Zealand Intensive Care Society Clinical Trials G, United Kingdom Critical Care Research G, Canadian Nephrology Trials N, Irish Critical Care Trials G, et al. Timing of Initiation of Renal-Replacement Therapy in Acute Kidney Injury. *N Engl J Med.* 2020;383:240–51.
 137. Zhang Z, Maddukuri G, Jaipaul N, Cai CX. Role of renal replacement therapy in patients with type 1 hepatorenal syndrome receiving combination treatment of vasoconstrictor plus albumin. *J Crit Care.* 2015;30:969–74.
 138. Paine CH, Pichler RH. Intraoperative Renal Replacement Therapy for Liver Transplantation: Is There Really a Benefit? *Liver Transpl.* 2020;26:971–2.
 139. Huang HB, Xu Y, Zhou H, Zhu Y, Qin JP. Intraoperative Continuous Renal Replacement Therapy During Liver Transplantation: A Meta-Analysis. *Liver Transpl.* 2020;26:1010–8.
 140. Karvellas CJ, Taylor S, Bigam D, Kneteman NM, Shapiro AMJ, Romanovsky A, et al. Intraoperative continuous renal replacement therapy during liver transplantation: A pilot randomized-controlled trial (INCEPTION). *Can J Anaesth.* 2019;66:1151–61.
 141. Piano S, Gambino C, Vettore E, Calvino V, Tonon M, Boccagni P, et al. Response to Terlipressin and Albumin Is Associated With Improved Liver Transplant Outcomes in Patients With Hepatorenal Syndrome. *Hepatology.* 2021;73:1909–19.